Methods for modulating angiogenesis
Recombinant plasminogen activator inhibitor-1 (PAI-1) isoforms which lack the reactive center loop and contain the complete heparin-binding domain or lack at least a portion of the heparin-binding domain are described. The rPAI-1 isoforms disclosed herein may be used to modulate angiogenesis through blocking release of VEGF from a VEGF-heparin complex. Furthermore, the rPAI-1 proteins may be used to inhibit cell proliferation and migration, induce apoptosis, and produce proteolytic fragments corresponding to angiostatin kringles 1-3 and kringles 1-4. A truncated proteolytic plasmin protein of 34 kDa is also provided.
1. A method for decreasing angiogenesis comprising administering an effective amount of a plasminogen activator inhibitor type 1 isoform lacking a reactive center loop and lacking a heparin-binding domain so that angiogenesis is decreased, wherein the amino acid sequence of said plasminogen activator inhibitor type 1 isoform is set forth in SEQ ID NO:3 or SEQ ID NO:7.
2. A method for decreasing angiogenesis comprising administering an effective amount of a plasminogen activator inhibitor type 1 isoform lacking a reactive center loop and lacking at least a portion of a heparin-binding domain so that angiogenesis is decreased, wherein the plasminogen activator inhibitor type isoform inhibits the release of VEGF from a VEGF-heparin complex thereby decreasing angiogenesis and wherein the amino acid sequence of said plasminogen activator inhibitor type 1 isoform is set forth in SEQ ID NO:4 or SEQ ID NO:8.
3. A method of promoting plaque regression comprising administering an effective amount of a plasminogen activator inhibitor type isoform lacking a reactive center loop and lacking at least a portion of the heparin-binding domain thereby promoting plaque regression, wherein the amino acid sequence of said plasminogen activator inhibitor type 1 isoform is set forth in SEQ ID NO:4 or SEQ ID NO:8.
4. A method of inducing angiostatin formation comprising administering an effective amount of a plasminogen activator inhibitor type isoform lacking a reactive center loop and lacking a heparin-binding domain so that the formation of angiostatin is induced, wherein the amino acid sequence of said plasminogen activator inhibitor type 1 isoform is set forth in SEQ ID NO:3 or SEQ ID NO:7.
5. A method of treating an angiogenesis-mediated disease comprising administering an effective amount of a plasminogen activator inhibitor type isoform lacking a reactive center loop and lacking at least a portion of a heparin-binding domain so that the signs or symptoms associated with the angiogenesis-mediated disease are reduced, wherein the amino acid sequence of said plasminogen activator inhibitor type 1 isoform is set forth in SEQ ID NO:4 or SEQ ID NO:8.